Evidence supporting the use of: Phaseolamin
For the health condition: Appetite (excessive)
Synopsis
Source of validity: Scientific
Rating (out of 5): 2
Phaseolamin is a protein extract derived from the white kidney bean (Phaseolus vulgaris) and is primarily known for its ability to inhibit alpha-amylase, an enzyme responsible for breaking down carbohydrates into sugars. The rationale for its use in supporting or treating excessive appetite is grounded in its potential to reduce the absorption of carbohydrates, which may, in turn, modulate blood glucose and insulin responses after meals. This modulation is hypothesized to help control hunger and reduce overall caloric intake.
Several small clinical trials and animal studies have investigated the effects of Phaseolamin or white kidney bean extract on weight management and appetite control. While the majority of studies focus on weight loss and carbohydrate absorption rather than direct appetite suppression, some research suggests that by blunting postprandial glucose spikes, Phaseolamin may indirectly reduce subsequent hunger.
However, the evidence base is relatively modest. Most studies are short-term, involve small sample sizes, and often combine Phaseolamin with other ingredients, making it difficult to attribute effects solely to Phaseolamin. There is some scientific rationale and preliminary evidence, but robust, long-term randomized controlled trials specifically measuring appetite reduction are lacking. Therefore, while there is some scientific validation for its use in this context, the evidence is limited and best described as preliminary.
Other health conditions supported by Phaseolamin
Appetite (excessive)Cholesterol (high)
Diabetes
Fat Metabolism (poor)
Weight Loss